ClinicalTrials.gg
RecruitingNCT07884175Updated Nov 13, 2026

A Study of Updated mRNA Seasonal Influenza Vaccines

A Phase 4 interventional study of mRNA-1010 and Licensed High-Dose Seasonal Influenza Vaccine in Seasonal Influenza, sponsored by ModernaTX, Inc.. Recruiting at 4 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 13, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Planned enrollment
10th of 12
200 · median 471
Started
2026
with 1 other
Phase 4
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is the only one in phase 4, and was the 12th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of updated strain-containing compositions of the mRNA-1010 vaccines within the current epidemiological environment.

Read the detailed description

This study uses a master protocol with a generic study design to allow flexibility in evaluating immunogenicity and safety of updated strain-containing compositions of the mRNA-1010 vaccines. As different strain-containing vaccine compositions will be evaluated, each study intervention will be described in the subprotocol. For each evaluation of an updated strain, a new subprotocol will be generated. Reported outcome measures are based upon each subprotocol. Not all reported outcome measures may be applicable to each subprotocol.

Subprotocol 01 is to evaluate the 2026-2027 mRNA influenza vaccine.

03

Conditions studied

  • Seasonal Influenza

Browse trials for

Keywords

  • Flu
  • Influenza
  • Vaccine
  • mRNA vaccine
  • mRNA-1010
  • Moderna
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  • Female participants must be of non-.

Key Exclusion Criteria:

  • Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4° Fahrenheit [F]]) within 72 hours prior to at the Screening Visit or Day 1.
  • History of anaphylaxis or severe reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, could interfere with interpretation of study results or limit the participant's participation in the study.
  • History of myocarditis, pericarditis, or myopericarditis within 90 days prior to Day 1 (Baseline).
  • Received at ≥10 mg/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 (Baseline) or within 28 days after Day 1.
  • Received systemic treatment, including long-acting biological therapies that affect immune responses (eg, infliximab), within 180 days prior to Day 1 (Baseline) or plans to do so during the study.
  • Tested positive for influenza by US Centers for Disease Control and Prevention (CDC)-recommended testing methods within 180 days prior to Day 1.
  • Received systemic immunoglobulins or blood products within 90 days prior to Day 1 (Baseline) or plans to do so during the study.
  • Received any vaccine (excluding seasonal influenza vaccine) authorized or approved by local health agency within 28 days prior to Day 1 (Baseline) or plans to do so within 14 days after Day 1 (Baseline).
  • Received a licensed or seasonal influenza vaccine within 6 months prior to Day 1 (Baseline) or plans to do so (outside of this study) at any time during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    mRNA-1010 Influenza Strain-containing Composition (2026- 2027)

    Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Active comparator
    Licensed High-Dose Seasonal Influenza Vaccine

    Participants will receive a single dose of licensed high-dose seasonal influenza vaccine by IM injection on Day 1.

    Biological: Licensed High-Dose Seasonal Influenza Vaccine

Interventions

  • BiologicalmRNA-1010

    Sterile liquid for injection

  • BiologicalLicensed High-Dose Seasonal Influenza Vaccine

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay

    Time frame: Day 29

  2. Number of Participants Reaching Seroconversion at Day 29 as Measured by HAI Assay

    Seroconversion is defined as a Day 29 titer ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in anti-HA antibodies measured by HAI assay.

    Time frame: Day 29

  3. Number of Participants with an HAI Titer ≥1:40 at Day 29

    Time frame: Day 29

  4. Geometric Mean Fold Rise (GMFR), as Measured by HAI Assay

    Time frame: Baseline to Day 29

Secondary outcomes

  1. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Day 1 through Day 29

  2. Number of Participants with Serious AEs, Medical-attended AEs and AE of Interest, and AEs Leading to Discontinuation

    Time frame: Day 1 through Day 29

07

Study locations

4 of 4 sites recruiting
  • Arizona Clinical Trials
    Tucson, Arizona 85711, United States
    Recruiting
  • Johnson County Clin-Trials LLC (JCCT)
    Lenexa, Kansas 66219, United States
    Recruiting
  • DelRicht Research at Derby City Direct Primary Care
    Louisville, Kentucky 40205, United States
    Recruiting
  • DelRicht Research at Amy Roberts MD and Associates
    Town and Country, Missouri 63017, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2026, 1 month after the start.

Of 37 industry-sponsored phase 4 interventional studies under Influenza, Human, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's planned 1 month is below that.

Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Oct 20, 2026
StartActual
Oct 15, 2026
Primary completionEst.
Dec 7, 2026
CompletionEst.
Dec 7, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Arizona Clinical Trials · Tucson, United States
  • Johnson County Clin-Trials LLC (JCCT) · Lenexa, United States
  • DelRicht Research at Derby City Direct Primary Care · Louisville, United States
  • DelRicht Research at Amy Roberts MD and Associates · Town and Country, United States
Nov 13, 2026
Registered
First appeared on the registry
Oct 20, 2026
Show all 2 updates
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    4 sites added — first site in United States
    Show 4 added (4 United States)
    • Arizona Clinical Trials · Tucson, United States
    • Johnson County Clin-Trials LLC (JCCT) · Lenexa, United States
    • DelRicht Research at Derby City Direct Primary Care · Louisville, United States
    • DelRicht Research at Amy Roberts MD and Associates · Town and Country, United States
    + 2 other changes: verification date and date precision
  2. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07884175
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Oct 15, 2026
Primary completion
Dec 7, 2026 (estimated)
Completion
Dec 7, 2026 (estimated)
Last update
Nov 13, 2026

Study contacts

Moderna WeCare Team
Contact
WeCareClinicalTrials@modernatx.com
1-866-663-3762

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1010 influenza vaccine

Start the discussion